Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis

被引:0
作者
Hongxia Jia
Lili Yu
Bin Gao
Qiuhe Ji
机构
[1] Fourth Military Medical University,Department of Endocrinology and Metabolism, Xijing Hospital
[2] Jinan General Hospital,Department of Information Technology
来源
Endocrine | 2011年 / 40卷
关键词
Diabetic nephropathy; Meta-analysis; Polymorphism;
D O I
暂无
中图分类号
学科分类号
摘要
Accumulating evidence has suggested that transforming growth factor-beta 1 (TGF-β1) is a functional candidate for diabetic nephropathy (DN). However, association studies investigating the relationship of TGF-β1 gene T869C polymorphism and DN generate inconsistent results. To comprehensively clarify this issue, we performed a meta-analysis to evaluate the impact of the polymorphism on DN. We searched studies from PubMed and China National Knowledge Infrastructure (CNKI) through March 2011. Pooled ORs were calculated under allelic/additive/dominant/recessive/over-dominant genetic models. Nine studies with 1776 cases and 1740 controls were included. Our results indicated that C allele of T869C conferred a significantly increased risk of DN compared with T allele (OR = 1.25, 95% CI: 1.05–1.48) for allelic contrast. Similar results were also found under additive (OR = 1.57, 95% CI: 1.10–2.23) and dominant (OR = 1.40, 95% CI: 1.06–1.85) genetic models. However, subgroup analyses stratified by types of diabetes showed that significantly increased risks were only observed in type 2 diabetic patients, and the association persistently existed in further analysis for Asian populations. As for type 1 diabetic subjects, no significant association was detected under all the genetic models (P > 0.05). Our meta-analysis suggested that the TGF-β1 T869C polymorphism conferred an elevated risk of DN. However, significant associations were only observed in type 2 diabetic patients.
引用
收藏
页码:372 / 378
页数:6
相关论文
共 175 条
[1]  
Jawa A(2004)Diabetic nephropathy and retinopathy Med. Clin. North. Am. 88 1001-1036
[2]  
Kcomt J(2002)Clinical practice. Nephropathy in patients with type 2 diabetes N. Engl. J. Med. 346 1145-1151
[3]  
Fonseca VA(2007)Molecular mechanisms of diabetic nephropathy and its therapeutic intervention Curr. Drug Targets 8 952-959
[4]  
Remuzzi G(2008)Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy Diabetes Res. Clin. Pract. 82 S38-S41
[5]  
Schieppati A(1993)Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl. Acad. Sci. USA 90 1814-1818
[6]  
Ruggenenti P(1996)Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease Lab. Investig. 74 991-1003
[7]  
Yamagishi S(2000)Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice Proc. Natl. Acad. Sci. USA 97 8015-8020
[8]  
Fukami K(1996)Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice Diabetes 45 522-530
[9]  
Ueda S(1986)Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7 Somat. Cell Mol. Genet. 12 281-288
[10]  
Okuda S(1998)Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women J. Bone Miner. Res. 13 1569-1576